Samira Daswani is CEO of Manta Cares. Her career in consulting and digital health startups took a left turn when she was diagnosed with breast cancer and had 18 months of visits with 123 appointments, 5 ER visits and much more. And it was very hard to manage her journey. So she built a paper based map/guide and started distributing it via hospitals in the gift shops and elsewhere. Manta Cares is the digital instantiation of that cancer map with symptom tracking and an AI chatbot on top of the map. Samira demoed it extensively for me. She raised some seed funding, and is now building it out for 80% of cancers–Matthew Holt
Adrian Owen & Faraz Shafaghi, Creyos
I spoke with neuroscientist Adrian Owen, co-founder and Chief Scientific Officer & Faraz Shafaghi, Chief Product Officer, at neurological testing company Creyos (which rhymes with “chaos”). Their cognitive assessment platform gives a baseline of neurological function and is essentially getting objective data at a point of care. This can now be done as part of the annual wellness visit (in fact it’s officially required under Medicare!), and there are things you can do about it. We dove into how it works, Faraz showed a whole demo of the test itself, Adrian explained what the impact of testing will be, and they shared Creyos’ progress in moving into practice.–Matthew Holt
Dayne Williams, Quantum Health
Quantum Health is one of the biggest and original navigation companies. Dayne Williams came out of retirement to take over as CEO after Zane Burke retired for personal reasons (to care for a relative). Quantum has in recent months added two acquisitions, Embold Health that analyzes which are the best doctors to go to, and CirrusMD which is a online telehealth & primary care company. I started though asking Dayne, with health plans and primary care docs, why do we need navigators? That’s a layup for him, but this is a great explanation of how Quantum is the front door/first call for the employees of its clients–what they call first time intercept–and where it’s going with that trust–Matthew Holt
Philippe Pouletty, Carvolix
Philippe Pouletty is a physician who’s an inventor, French venture capitalist, and the founder of Carvolix. Carvolix is a medical technology company that is introducing AI into cardiology. Before Carvolix, Philippe was the founder of Abivax, which makes drugs for chronic inflammatory diseases like ulcerative colitis. He’s been working on helping French medical products develop before having to sell to bigger US companies, and Carvolix is the latest. It’s an AI system that guides cardiologists and a robot that places heart valves. It’s of particular interest to me, as I need a new heart valve. I had a long and interesting discussion with Philippe about the future of cardiology, particularly heart valve replacement, and also about their upcoming product, a robot to bust brain clots–Matthew Holt
Peter Stetson, TigerConnect
Peter Stetson is the CMIO of TigerConnect. It’s now calling itself an AI platform to connect people, especially workflows between doctors, nurses, EMTs and devices. Until recently he was CMIO at Memorial Sloan Kettering, so I asked him about what the real problems in communications were. He believes it’s all about routing the calls to the right people and figuring out which is the right person to get the message escalation based on context. That can be in the hospital, or in the home. Tiger’s evolution has been to work on that orchestration. Peter gave the example of orchestrating surgery to improve patient care & save hospitals money, but similar issues are triggered by sepsis, heart attacks, etc, all in the Tiger system, increasingly automated off devices. And I raised the issue of where does Epic stop and where does Tiger start. Always controversial these days. But Peter is confident Tiger is “safe” for now!—Matthew Holt
Cody Simmons, DermaSensor
Cody Simmons is the CEO of DermaSensor. I met him when he won the Digital Health Hub Foundation award for diagnostic tools last year. DermaSensor is a device designed to detect early skin cancer using Spectroscopy. Right now only 8% of those with potential skin cancer get the recommended screening. It’s another area where technology can potentially democratize medicine. DermaSensor is aiming for the primary care market. Cody shows how the tool works and explains how the PCP can both improve screening for their patients, and also make money from doing that–otherwise of course they wouldn’t do it! As you can imagine both the technology, the FDA approval process and the roll-out is pretty complicated. Cody explains all–Matthew Holt
Tom Kelly, Heidi Health
Tom Kelly is the CEO of Heidi Health, another of the many ambient AI scribes that is spreading its wings to other roles, including bringing its own AI Open Evidence competitor! He calls it an AI care partner. Heidi started in Australia, and quickly moved to the UK and Canada, but now are in over one hundred countries. More recently they have come to the US and have now four major health systems and a lot of other mid market users. Tom think’s Heidi will soon do all the “work around the work”, and he doesn’t think it has to be deeply integrated with the EMR. He sees that as a superpower as doctors don’t want to be in the record. Is he right? Are scribes and ambient AI going to be separate? Does the scribe have to be a medical device, as it does in the UK? Will patients use it? Lots of questions about the future and Tom has lots of answers. Some might even be right!–Matthew Holt
Kevin Wang, Suki
Suki is one of the original Ambient scribing, now Ambient intelligence, companies. They’re selling both to providers and to other partners using their tech in their tools and services (think telehealth, other EHR providers like Athena, and more). Kevin Wang is the Chief Medical Officer, and he told me about the evolution of ambient documentation, how it makes doctors happy, and how it’s now moving into improving coding (and billing) but will soon be moving into improving clinical decision support. We haggled a little about the ROI from Ambient and where that comes from (remembering codes), and discussed how the EMR v Ambient plays out. And we talked a little about what the impact of ambient and AI will be on medicine…–Matthew Holt
Ian Shakil, Commure
Ian Shakil is the Chief Strategy Officer of Commure, the AI platform being used by HCA, Tenet and others. He came to Commure via its acquisition of Ambient AI vendor Augmedix, and there are a lot other other new acquisitions within Commure (Athelas, PatientKeeper, Memora Health, Rx Health etc). We dived in not only about what Commure does but the big question of how does a client like HCA or Tenet decide what Commure does, vs what Meditech does, vs what Google does vs what they do internally. We also (sorta) looked into the various criticisms (basically all from Sergei Polevikov!) of what Commure and its main funder General Catalyst are up to and what is happening at Summa Health the hospital in Ohio that GC bought. He also says the good experience from AI will come to help patients this year, and I’ll be holding him to that!–Matthew Holt
Jason Prestinario, Particle Health
Jason Prestinario is CEO of Particle Health. The company is best known for its current lawsuit against Epic, but behind that there is a real company delivering a set of products as on ramp for clients wanting to access health data. Particle was cut off from access to Carequality & Epic a couple of years back but is now both delivering services to its customers and separately suing Epic for being an abusive monopoly regarding its payer platform. I had written about this a couple of years ago but I used this chance to catch up with Jason, to see what the sate of play was. He explained that Carequality said that Particle was right in the original dispute, and why they were right and Epic was wrong. The court case continues. But it’s interesting to hear from someone in the middle of the new disputes about data. — Matthew Holt
